Cord Stem Cell Banking Market 2020 Industry Share, Size, Growth, Segments, Revenue, Statistics, Busi – PharmiWeb.com

Global Cord stem cell banking market is estimated to reach USD 13.8 billion by 2026 registering a healthy CAGR of 22.4%. The increasing number of parents storing their childs cord blood, acceptance of stem cell therapeutics, high applicability of stem cells are key driver to the market.

Request for FREE sample copy or PDF Here https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-cord-stem-cell-banking-market

Few of the major market competitors currently working in the globalcord stem cell banking marketareCBR Systems, Inc., Cordlife, Cells4Life Group LLP, Cryo-Cell International, Inc., Cryo-Save AG, Lifecell, StemCyte India Therapeutics Pvt. Ltd, Viacord, SMART CELLS PLUS., Cryoviva India, Global Cord Blood Corporation, National Cord Blood Program, Vita 34, ReeLabs Pvt. Ltd., Regrow Biosciences Pvt. Ltd. , ACROBiosystems., Americord Registry LLC., New York Blood Center, Maze Cord Blood, GoodCell., AABB, Stem Cell Cryobank, New England Cryogenic Center, Inc. among others

Market Definition: Global Cord Stem Cell Banking Market

Cord stem cells banking is nothing but the storing of the cord blood cell contained in the umbilical cord and placenta of a newborn child. This cord blood contains the stem cells which can be used in future to treat disease such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, and few others.

Browse Detailed TOC, Tables, Figures, Charts and Companies @https://www.databridgemarketresearch.com/toc?dbmr=global-cord-stem-cell-banking-market

Segmentation: Global Cord Stem Cell Banking Market

Cord Stem Cell banking Market : By Storage Type

Cord Stem Cell banking Market : By Product Type

Cord Stem Cell banking Market : By Service Type

Cord Stem Cell banking Market : By Indication

Cord Stem Cell banking Market : By Source

Cord Stem Cell banking Market : By Geography

Key Developments in the Cord Stem Cell banking Market:

This Cord Stem Cell Banking Market report includes a wide-ranging evaluation of the markets growth prospects and restrictions. The Cord Stem Cell Banking Market report provides estimations about the growth rate and the market value in industry based on market dynamics and growth inducing factors. Global Cord Stem Cell Banking Market report studies the industry abilities for each geographical region based on the customer purchasing patterns, macroeconomic parameters, development rate, and market demand and supply states. In addition, this Cord Stem Cell Banking Market report also endows with top to bottom estimation of the market with respect to income and developing business sector.

For market segmentation study performed in this Cord Stem Cell Banking Market report, a market of potential customers is classified into groups or segments based on different characteristics such as application of product, deployment model, end user and geographical region etc. The report contains a number of market drivers and restraints which are obtained from SWOT analysis and all the CAGR projections for the historic year 2018, base year 2019, and forecast period of 2020-2027. The report also highlights the reviews about key players, major collaborations, merger & acquisitions along with trending innovation and business policies. It is also assured that the report provides precise market segmentation and insights for the success of business.

Scope of the Cord Stem Cell banking Market Report :

The report shields the development activities in the Cord Stem Cell banking Market which includes the status of marketing channels available, and an analysis of the regional export and import. It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments. This will benefit the reports users, that evaluates their position in Cord Stem Cell banking market as well as create effective strategies in the near future.

Cord Stem Cell Banking Market Reports Table of Contents

Want Full Report? Enquire Here @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-cord-stem-cell-banking-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Follow this link:

Cord Stem Cell Banking Market 2020 Industry Share, Size, Growth, Segments, Revenue, Statistics, Busi - PharmiWeb.com

Read more
Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2021 – PRNewswire

HONG KONG, Nov. 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the second quarter and first half of fiscal 2021 ended September 30, 2020.

Second Quarter of Fiscal 2021 Highlights

First Half of Fiscal 2021 Highlights

"We successfully managed to recruit 17,643 new subscribers in the second quarter, keeping us on track to meet our annual target despite challenges associated with Covid-19, a downward trend in newborns and an overall cautious consumer environment," said Ms. Ting Zheng, Chairperson and Chief Executive Officer of GCBC. "Although future regulation in the cord blood banking industry in China remains unclear, we continue to prepare for multiple potential outcomes and carry on with our business expansion and risk diversification efforts."

Summary Second Quarter and First Half Ended September 30, 2019 and 2020

Three Months Ended September 30,

Six Months Ended September 30,

2019

2020

2019

2020

(in thousands)

RMB

RMB

US$

RMB

RMB

US$

Revenues

313,464

285,607

42,066

586,839

566,520

83,440

Gross Profit

265,149

240,909

35,483

492,775

478,359

70,455

Operating Income[3]

144,435

139,161

20,497

256,821

272,670

40,163

Change in Fair Value of

Equity Securities

(7,043)

5,699

839

2,936

24,104

3,550

Dividend Income

-

1,281

189

507

1,281

189

Net Income Attributable tothe Company's Shareholders

120,353

131,434

19,360

228,697

263,943

38,877

Earnings per Ordinary

Share (RMB/US$)

Basic

0.99

1.08

0.16

1.88

2.17

0.32

Diluted

0.99

1.08

0.16

1.88

2.17

0.32

Revenues Breakdown (%)

Processing Fees and Other

Services

63.9%

57.5%

62.7%

57.5%

Storage Fees

36.1%

42.5%

37.3%

42.5%

New Subscribers (persons)

21,551

17,643

42,366

34,876

Total Accumulated Subscribers(persons)

791,812

867,180[1]

791,812

867,180[1]

Summary Selected Cash Flow Statement Items

View original post here:

Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2021 - PRNewswire

Read more
Stem Cell Banking Outsourcing Market 2020-2026- Business Insights, Trends and Key Drivers| CCBC, CBR, ViaCord – The Haitian-Caribbean News Network

The global Stem Cell Banking Outsourcing market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Stem Cell Banking Outsourcing market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global Stem Cell Banking Outsourcing market. The authors of the report profile leading companies of the global Stem Cell Banking Outsourcing market, such as CCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife Group, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech Group, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell They provide details about important activities of leading players in the competitive landscape.

The report predicts the size of the global Stem Cell Banking Outsourcing market in terms of value and volume for the forecast period 2019-2026. As per the analysis provided in the report, the global Stem Cell Banking Outsourcing market is expected to rise at a CAGR of XX % between 2019 and 2026 to reach a valuation of US$ XX million/billion by the end of 2026. In 2018, the global Stem Cell Banking Outsourcing market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global Stem Cell Banking Outsourcing industry landscape and the future prospects it is anticipated to create.

This publication includes key segmentations of the global Stem Cell Banking Outsourcing market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

Get Sample Copy of This Report:https://www.qyresearch.com/sample-form/form/2304658/global-stem-cell-banking-outsourcing-market

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global Stem Cell Banking Outsourcing market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global Stem Cell Banking Outsourcing market.

Readers can understand the overall profitability margin and sales volume of various products studied in the report. The report also provides the forecasted as well as historical annual growth rate and market share of the products offered in the global Stem Cell Banking Outsourcing market. The study on end-use application of products helps to understand the market growth of the products in terms of sales.

Global Stem Cell Banking Outsourcing Market by Product: Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other

Global Stem Cell Banking Outsourcing Market by Application: , Diseases Therapy, Healthcare

The report also focuses on the geographical analysis of the global Stem Cell Banking Outsourcing market, where important regions and countries are studied in great detail.

Global Stem Cell Banking Outsourcing Market by Geography:

Methodology

Our analysts have created the report with the use of advanced primary and secondary research methodologies.

As part of primary research, they have conducted interviews with important industry leaders and focused on market understanding and competitive analysis by reviewing relevant documents, press releases, annual reports, and key products.

For secondary research, they have taken into account the statistical data from agencies, trade associations, and government websites, internet sources, technical writings, and recent trade information.

Enquire For Customization in the Report:https://www.qyresearch.com/customize-request/form/2304658/global-stem-cell-banking-outsourcing-market

Key questions answered in the report:

Get Full Report in your Inbox within 24 Hours at USD(3350): https://www.qyresearch.com/settlement/pre/97a1ea508f0016903da030c8aa4b6303,0,1,global-stem-cell-banking-outsourcing-market

Table Of Contents:

1 Market Overview of Stem Cell Banking Outsourcing1.1 Stem Cell Banking Outsourcing Market Overview1.1.1 Stem Cell Banking Outsourcing Product Scope1.1.2 Market Status and Outlook1.2 Global Stem Cell Banking Outsourcing Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Stem Cell Banking Outsourcing Market Size by Region (2015-2026)1.4 Global Stem Cell Banking Outsourcing Historic Market Size by Region (2015-2020)1.5 Global Stem Cell Banking Outsourcing Market Size Forecast by Region (2021-2026)1.6 Key Regions, Stem Cell Banking Outsourcing Market Size YoY Growth (2015-2026)1.6.1 North America Stem Cell Banking Outsourcing Market Size YoY Growth (2015-2026)1.6.2 Europe Stem Cell Banking Outsourcing Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific Stem Cell Banking Outsourcing Market Size YoY Growth (2015-2026)1.6.4 Latin America Stem Cell Banking Outsourcing Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa Stem Cell Banking Outsourcing Market Size YoY Growth (2015-2026) 2 Stem Cell Banking Outsourcing Market Overview by Type2.1 Global Stem Cell Banking Outsourcing Market Size by Type: 2015 VS 2020 VS 20262.2 Global Stem Cell Banking Outsourcing Historic Market Size by Type (2015-2020)2.3 Global Stem Cell Banking Outsourcing Forecasted Market Size by Type (2021-2026)2.4 Umbilical Cord Blood Stem Cell2.5 Embryonic Stem Cell2.6 Adult Stem Cell2.7 Other 3 Stem Cell Banking Outsourcing Market Overview by Application3.1 Global Stem Cell Banking Outsourcing Market Size by Application: 2015 VS 2020 VS 20263.2 Global Stem Cell Banking Outsourcing Historic Market Size by Application (2015-2020)3.3 Global Stem Cell Banking Outsourcing Forecasted Market Size by Application (2021-2026)3.4 Diseases Therapy3.5 Healthcare 4 Global Stem Cell Banking Outsourcing Competition Analysis by Players4.1 Global Stem Cell Banking Outsourcing Market Size by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Stem Cell Banking Outsourcing as of 2019)4.3 Date of Key Manufacturers Enter into Stem Cell Banking Outsourcing Market4.4 Global Top Players Stem Cell Banking Outsourcing Headquarters and Area Served4.5 Key Players Stem Cell Banking Outsourcing Product Solution and Service4.6 Competitive Status4.6.1 Stem Cell Banking Outsourcing Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 CCBC5.1.1 CCBC Profile5.1.2 CCBC Main Business5.1.3 CCBC Stem Cell Banking Outsourcing Products, Services and Solutions5.1.4 CCBC Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.1.5 CCBC Recent Developments5.2 CBR5.2.1 CBR Profile5.2.2 CBR Main Business5.2.3 CBR Stem Cell Banking Outsourcing Products, Services and Solutions5.2.4 CBR Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.2.5 CBR Recent Developments5.3 ViaCord5.5.1 ViaCord Profile5.3.2 ViaCord Main Business5.3.3 ViaCord Stem Cell Banking Outsourcing Products, Services and Solutions5.3.4 ViaCord Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.3.5 Esperite Recent Developments5.4 Esperite5.4.1 Esperite Profile5.4.2 Esperite Main Business5.4.3 Esperite Stem Cell Banking Outsourcing Products, Services and Solutions5.4.4 Esperite Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.4.5 Esperite Recent Developments5.5 Vcanbio5.5.1 Vcanbio Profile5.5.2 Vcanbio Main Business5.5.3 Vcanbio Stem Cell Banking Outsourcing Products, Services and Solutions5.5.4 Vcanbio Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.5.5 Vcanbio Recent Developments5.6 Boyalife5.6.1 Boyalife Profile5.6.2 Boyalife Main Business5.6.3 Boyalife Stem Cell Banking Outsourcing Products, Services and Solutions5.6.4 Boyalife Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.6.5 Boyalife Recent Developments5.7 LifeCell5.7.1 LifeCell Profile5.7.2 LifeCell Main Business5.7.3 LifeCell Stem Cell Banking Outsourcing Products, Services and Solutions5.7.4 LifeCell Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.7.5 LifeCell Recent Developments5.8 Crioestaminal5.8.1 Crioestaminal Profile5.8.2 Crioestaminal Main Business5.8.3 Crioestaminal Stem Cell Banking Outsourcing Products, Services and Solutions5.8.4 Crioestaminal Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.8.5 Crioestaminal Recent Developments5.9 RMS Regrow5.9.1 RMS Regrow Profile5.9.2 RMS Regrow Main Business5.9.3 RMS Regrow Stem Cell Banking Outsourcing Products, Services and Solutions5.9.4 RMS Regrow Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.9.5 RMS Regrow Recent Developments5.10 Cordlife Group5.10.1 Cordlife Group Profile5.10.2 Cordlife Group Main Business5.10.3 Cordlife Group Stem Cell Banking Outsourcing Products, Services and Solutions5.10.4 Cordlife Group Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.10.5 Cordlife Group Recent Developments5.11 PBKM FamiCord5.11.1 PBKM FamiCord Profile5.11.2 PBKM FamiCord Main Business5.11.3 PBKM FamiCord Stem Cell Banking Outsourcing Products, Services and Solutions5.11.4 PBKM FamiCord Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.11.5 PBKM FamiCord Recent Developments5.12 cells4life5.12.1 cells4life Profile5.12.2 cells4life Main Business5.12.3 cells4life Stem Cell Banking Outsourcing Products, Services and Solutions5.12.4 cells4life Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.12.5 cells4life Recent Developments5.13 Beikebiotech5.13.1 Beikebiotech Profile5.13.2 Beikebiotech Main Business5.13.3 Beikebiotech Stem Cell Banking Outsourcing Products, Services and Solutions5.13.4 Beikebiotech Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.13.5 Beikebiotech Recent Developments5.14 StemCyte5.14.1 StemCyte Profile5.14.2 StemCyte Main Business5.14.3 StemCyte Stem Cell Banking Outsourcing Products, Services and Solutions5.14.4 StemCyte Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.14.5 StemCyte Recent Developments5.15 Cryo-cell5.15.1 Cryo-cell Profile5.15.2 Cryo-cell Main Business5.15.3 Cryo-cell Stem Cell Banking Outsourcing Products, Services and Solutions5.15.4 Cryo-cell Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.15.5 Cryo-cell Recent Developments5.16 Cellsafe Biotech Group5.16.1 Cellsafe Biotech Group Profile5.16.2 Cellsafe Biotech Group Main Business5.16.3 Cellsafe Biotech Group Stem Cell Banking Outsourcing Products, Services and Solutions5.16.4 Cellsafe Biotech Group Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.16.5 Cellsafe Biotech Group Recent Developments5.17 PacifiCord5.17.1 PacifiCord Profile5.17.2 PacifiCord Main Business5.17.3 PacifiCord Stem Cell Banking Outsourcing Products, Services and Solutions5.17.4 PacifiCord Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.17.5 PacifiCord Recent Developments5.18 Americord5.18.1 Americord Profile5.18.2 Americord Main Business5.18.3 Americord Stem Cell Banking Outsourcing Products, Services and Solutions5.18.4 Americord Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.18.5 Americord Recent Developments5.19 Krio5.19.1 Krio Profile5.19.2 Krio Main Business5.19.3 Krio Stem Cell Banking Outsourcing Products, Services and Solutions5.19.4 Krio Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.19.5 Krio Recent Developments5.20 Familycord5.20.1 Familycord Profile5.20.2 Familycord Main Business5.20.3 Familycord Stem Cell Banking Outsourcing Products, Services and Solutions5.20.4 Familycord Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.20.5 Familycord Recent Developments5.21 Cryo Stemcell5.21.1 Cryo Stemcell Profile5.21.2 Cryo Stemcell Main Business5.21.3 Cryo Stemcell Stem Cell Banking Outsourcing Products, Services and Solutions5.21.4 Cryo Stemcell Stem Cell Banking Outsourcing Revenue (US$ Million) & (2015-2020)5.21.5 Cryo Stemcell Recent Developments 6 North America6.1 North America Stem Cell Banking Outsourcing Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe Stem Cell Banking Outsourcing Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific Stem Cell Banking Outsourcing Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America Stem Cell Banking Outsourcing Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa Stem Cell Banking Outsourcing Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 Stem Cell Banking Outsourcing Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View original post here:

Stem Cell Banking Outsourcing Market 2020-2026- Business Insights, Trends and Key Drivers| CCBC, CBR, ViaCord - The Haitian-Caribbean News Network

Read more
Impact Of Covid-19 On Stem Cell Banking Market 2020 Industry Challenges, By Key Players, Types, Applications, Countries, Market Size, Forecast To 2026…

Trending Stem Cell Banking Market 2020: COVID-19 Outbreak Impact Analysis

Chicago, United States The Stem Cell Banking market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations

The Stem Cell Banking market report 6 Years Forecast [2020-2026] focuses on the COVID19 Outbreak Impact analysis of key points influencing the growth of the market. The intelligence report prepared contains details on the leading players of the Global Stem Cell Banking Market, along with various depending aspects related and associated with the market. Profile the Top Key Players of Stem Cell Banking, with sales, revenue and global market share of Stem Cell Banking are analyzed emphatically by landscape contrast and speak to info. Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Stem Cell Banking market business development trends and selling channels square measure analyzed. Stem Cell Banking industry research report enriched on worldwide competition by topmost prime manufactures which providing information such as Company Profiles, Gross, Gross Margin, Capacity, Product Picture and Specification, Production, Price, Cost, Revenue and contact information.

>>>>>>This Report Covers Leading Companies Associated in Worldwide Stem Cell Banking Market: CCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife Group, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech Group, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell, Stemade Biotech>>>>>>To know How COVID-19 Pandemic Will Impact This Market/Industry | Request a sample copy of the Stem Cell Banking Market report:

Key Issues Addressed by Stem Cell Banking Market: The Stem Cell Banking report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. This report provides an in-depth analysis of parent company market trends, macroeconomic indicators and dominant factors, and market attractiveness by segment.

Our exploration specialists acutely ascertain the significant aspects of the global Stem Cell Banking market report. It also provides an in-depth valuation in regards to the future advancements relying on the past data and present circumstance of Stem Cell Banking market situation. In this Stem Cell Banking report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. The global Stem Cell Banking report comprises of primary and secondary data which is exemplified in the form of pie outlines, Stem Cell Banking tables, analytical figures, and reference diagrams. The Stem Cell Banking report is presented in an efficient way that involves basic dialect, basic Stem Cell Banking outline, agreements, and certain facts as per solace and comprehension.

Key point summary of the Stem Cell Banking market Report:

1) Examining the overall market, underlining the recent trends and SWOT analysis2) Stem Cell Banking Market scenario, focused on the growth opportunities in the market in the coming years3) Analysis of the different market segments, including qualitative and quantitative research and studies the impact of both economic and non-economic factors4) Inspection of the market at regional and global levels focusing on the demand and supply factors affecting the growth of the Stem Cell Banking market.5) Market size (USD Million) and volume (Units Million) statistics for all market segment and sub-segment6) Competitive analysis with Stem Cell Banking market share of leading market players, shedding light on project launches and tactical approaches implemented by the players in the last five years7) Extensive company profiling comprising of the product offerings, key financial facts and figures, recent developments, SWOT analysis, and strategic initiatives by the major firms in the Stem Cell Banking market

The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels.The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

Competitive Landscape:

The competitive analysis of major market players is another notable feature of the Stem Cell Banking market report; it identifies direct or indirect competitors in the market.

The Stem Cell Banking market report provides answers to the following key questions:

At what rate is the Stem Cell Banking market expected to grow in size in the forecast period? What are the key factors influencing the global Stem Cell Banking market growth? Which significant market trends are driving the growth of the global Stem Cell Banking market? Which factors are the determinants of the market shares of the leading geographies across the globe? Who are the leading participants in the industry and what are the strategies adopted by them in the global Stem Cell Banking market? What are the opportunities and challenges encounters by vendors in the global Stem Cell Banking market? Which trends, drivers and challenges are affecting the growth of the industry? What is the outcome of the PESTEL analysis of the global Stem Cell Banking market?

Analysis of Global Stem Cell Banking Market: By TypeDiseases TherapyEmbryonic Stem CellAdult Stem CellOthers

Analysis of Global Stem Cell Banking Market: By ApplicationDiseases TherapyHealthcare

Stem Cell Banking Market Regional Analysis Includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (the United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Strategic Points Covered in Table of Content of Global Stem Cell Banking Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Stem Cell Banking market

Chapter 2: Exclusive summary the basic information of the Stem Cell Banking Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Stem Cell Banking

Chapter 4: Presenting the Stem Cell Banking Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Stem Cell Banking market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source.

>>> Make an enquiry before buying this report @ https://www.reporthive.com/request_customization/2583417

Why Report Hive Research?:

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc.

Get in Touch with Us :

Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesWebsite: https://www.reporthive.comEmail: [emailprotected]Phone: +1 312-604-7084

Stem Cell Banking Market CAGR Competitive Landscape, Stem Cell Banking Market Analysis, Stem Cell Banking Market Best Companies in The world , Stem Cell Banking Market Status, Stem Cell Banking Market Supply, Stem Cell Banking Market Trend, Stem Cell Banking Trends ,Stem Cell Banking growth, Stem Cell Banking industry, Stem Cell Banking Covid-19 Impact Analysis

Visit link:

Impact Of Covid-19 On Stem Cell Banking Market 2020 Industry Challenges, By Key Players, Types, Applications, Countries, Market Size, Forecast To 2026...

Read more
Covid-19 Impact on Global Cell Banking Outsourcing Market Expected To Reach Highest CAGR by 2026 : SGS Life Sciences, Lonza, CCBC, Vcanbio, AMAG…

Predicting Growth Scope: Global Cell Banking Outsourcing Market

This Global Cell Banking Outsourcing Market report presented has been documented and mindfully articulated after ensuring thorough references of corporate websites, international journals, survey reports, besides engaging in detailed discussions and telephonic conversations with various stakeholders as well as company spokespersons, offering real-time on-field picture.

The report categorically identifies the region reflecting high investment returns. Additional information on R&D expeditions and vendor activities across diverse geographical hotspots.

Competition Spectrum:Our in-house research professionals have heavily relied upon primary and secondary research practices and methodologies to derive deductions.

which market players and aspiring new entrants may witness seamless entry.

SGS Life SciencesLonzaCCBCVcanbioAMAG PharmaceuticalsViaCordThermo FisherWuxi ApptecCordLifeEsperiteReliance Life SciencesLifecellCryo-CellToxikonGoodwin BiotechnologyTexcellCryo StemcellCell Banking Outsourcing

The overall Global Cell Banking Outsourcing market expanse is widely distributed across prominent growth hubs prevalent across regions such as North American and South American countries, European nations, besides several growth locales across MEA and APAC. The report illustrates impeccable contribution of these growth proficient regions, besides comprehending details on market share, growth forecasts, sales overview and revenue generation trends across each of the flagged growth beds across regions. Emphasis on market elements such as product portfolios, company strengths and weaknesses, production and consumption priorities as well as investment credentials have also been well discussed in this research report.

The report is designed to include versatile detailing of crude market aspects encompassing even elementary details and market segments comprising product type, services, applications and end-user profile.

Find full report and TOC here: @ https://www.orbisresearch.com/reports/index/covid-19-impact-on-global-cell-banking-outsourcing-market-size-status-and-forecast-2020-2026?utm_source=puja

Commercially viable investment deliverable potent mergers and acquisitions, product enhancement and portfolio diversification investments of leading players, as well as other contributing participants across various local markets, have also been pinned in this versatile report to encourage lucrative investments despite catastrophic developments and prevalent challenges and threats in global Cell Banking Outsourcing market isle.

The market is roughly segregated into:

Analysis by Product Type: The report includes in-detail references of all the notable product categories as well as application specifications. The product segment is described on the basis of key player development traits, sales overview, volume based returns and the like.

Stem Cell BankingNon-stem Cell BankingCell Banking Outsourcing

Application Analysis: Global Cell Banking Outsourcing market also specifically underpins end-use application scope and their improvements based on technological developments and consumer preferences.

Cell Bank StorageBank Characterization and TestingCell Bank Preparation

Segmentation by Region with details about Country-specific developments North America (U.S., Canada, Mexico) Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS) Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific) Latin America (Brazil, Rest of L.A.) Middle East and Africa (Turkey, GCC, Rest of Middle East)

Classified information documented in this report on global Cell Banking Outsourcing market is poised to encourage and motivate market participants and various other report readers towards deploying skillful business decisions aligning with futuristic industrial demands and transitioning customer needs.

The end-use segment is voluminous representation of product prices, gross margin analysis, market share and the like that tend to have holistic impact on the overall growth trail in the Cell Banking Outsourcing market as documented and presented in this research intensive report. The various elements such as market dynamics, market size and growth-related developments and key details on vendor listings, risks and challenges are also discussed at length in this versatile documentation on the Cell Banking Outsourcing market. The various risks, threats and growth barriers are also discussed in this report by research experts to encourage growth compliant business decisions.

Do You Have Any Query or Specific Requirement? Ask Our Industry [emailprotected] https://www.orbisresearch.com/contacts/enquiry-before-buying/4633254?utm_source=puja

This dedicated research report offering on the Cell Banking Outsourcing market presented by seasoned research practitioners sight crucial elements and all major and minor aspects including minute details on research methodologies, pricing, consumption and production ratios as well as supply chain networks that render favorable growth output in the global Cell Banking Outsourcing market.

Looking for provoking fruitful enterprise relationships with you!

About Us:Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

See the article here:

Covid-19 Impact on Global Cell Banking Outsourcing Market Expected To Reach Highest CAGR by 2026 : SGS Life Sciences, Lonza, CCBC, Vcanbio, AMAG...

Read more
Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2021 – Galveston County Daily News

HONG KONG, Nov. 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the second quarter and first half of fiscal 2021 ended September 30, 2020.

Second Quarter of Fiscal 2021 Highlights

Revenues decreased by 8.9% year-over-year ("YoY") to RMB285.6 million ($42.1 million).New subscribers and accumulated subscriber base were 17,643 and 867,180[1], respectively.Gross profit decreased by 9.1% YoY to RMB240.9 million ($35.5 million). Gross margin edged down slightly to 84.3% from 84.6% in the prior year period.Operating income decreased by 3.7% YoY to RMB139.2 million ($20.5 million). Operating margin increased to 48.7% from 46.1% in the prior year period.Operating income before depreciation and amortization ("non-GAAP operating income[2]") decreased by 3.5% YoY to RMB151.4 million ($22.3 million).Net income attributable to the Company's shareholders increased by 9.2% to RMB131.4 million ($19.4 million), largely due to an increase in fair value of equity securities ("mark-to-market gain").Net cash provided by operating activities was RMB174.8 million ($25.7 million).

First Half of Fiscal 2021 Highlights

Revenues decreased by 3.5% YoY to RMB566.5 million ($83.4 million).New subscribers and accumulated subscriber base were 34,876 and 867,180[1], respectively.Gross profit decreased by 2.9% YoY to RMB478.4 million ($70.5 million).Operating income increased by 6.2% YoY to RMB272.7 million ($40.2 million).Non-GAAP operating income[2] increased by 5.5% YoY to RMB297.3 million ($43.8 million).Net income attributable to the Company's shareholders increased by 15.4% to RMB263.9 million ($38.9 million), mainly due to the decrease in operating expenses and the mark-to-market gain in the six reporting months.Net cash provided by operating activities was RMB274.6 million ($40.5 million).

"We successfully managed to recruit 17,643 new subscribers in the second quarter, keeping us on track to meet our annual target despite challenges associated with Covid-19, a downward trend in newborns and an overall cautious consumer environment," said Ms. Ting Zheng, Chairperson and Chief Executive Officer of GCBC. "Although future regulation in the cord blood banking industry in China remains unclear, we continue to prepare for multiple potential outcomes and carry on with our business expansion and risk diversification efforts."

Summary Second Quarter and First Half Ended September 30, 2019 and 2020

Summary Selected Cash Flow Statement Items

Second Quarter of Fiscal 2021 Financial Results

REVENUES. Revenues decreased by 8.9% YoY to RMB285.6 million ($42.1 million) in the second quarter of fiscal 2021, as the decrease in revenues from processing fees and other services from fewer new subscribers outpaced growth in storage fee revenues.

Despite facing difficulties in the second quarter, the Company recruited 17,643 new subscribers. Revenues generated from processing fees and other services in the reporting quarter decreased by 18.1% YoY to RMB164.3 million ($24.2 million), representing 57.5% of total revenues compared to 63.9% in the prior year period.

The accumulated subscriber base as of September 30, 2020 expanded to 867,180[1]. Revenues generated from storage fees increased by 7.3% YoY to RMB121.3 million ($17.9 million) in the reporting quarter.

GROSS PROFIT. Gross profit for the second quarter decreased by 9.1% YoY to RMB240.9 million ($35.5 million). Gross margin decreased slightly to 84.3% from 84.6% in the prior year period, as raw material cost continued to exert margin pressure despite cost-saving efforts.

OPERATING INCOME. As cost-saving measures were implemented to counter the topline decrease, operating income for the reporting quarter decreased by 3.7% YoY to RMB139.2 million ($20.5 million). Operating margin improved to 48.7% from 46.1% in the prior year period, primarily due to measures taken to improve cost-efficiency. Depreciation and amortization expenses for the second quarter were RMB12.3 million ($1.8 million), representing a slight decrease from RMB12.5 million in the prior year period. Non-GAAP operating income[2] decreased by 3.5% YoY to RMB151.4 million ($22.3 million) in the reporting quarter.

Research and Development Expenses. Research and development expenses decreased to RMB5.0 million ($0.7 million) from RMB6.4 million in the prior year period.

Sales and Marketing Expenses. Sales and marketing expenses decreased to RMB54.1 million ($8.0 million) from RMB64.9 million in the prior year period, due to the Company's ongoing efforts to effectively manage its sales, marketing and promotional activities in light of weak demand. In particular, the reduction in sales force head count and remuneration, as well as fewer promotional activities, kept sales and marketing expenses in check with the topline reduction. Sales and marketing expenses as a percentage of revenues decreased to 19.0%, compared to 20.7% in the prior year period and 19.6% in the prior quarter.

General and Administrative Expenses. General and administrative expenses decreased by 13.7% YoY to RMB42.7 million ($6.3 million) as a result of lower staff costs and provisions. General and administrative expenses as a percentage of revenues decreased to 14.9% from 15.8% in the prior year period and 15.9% in the prior quarter.

OTHER INCOME AND EXPENSES.

Change in fair value of equity securities. In the reporting period, the Company recognized a mark-to-market gain of RMB5.7 million ($0.8 million), compared to a mark-to-market loss of RMB7.0 million in the prior year period. The changes were mainly attributable to the Company's investments in equity securities.

Dividend Income. In the second quarter, the Company received RMB1.3 million ($0.2 million) dividend income from the Company's equity investments, whereas no such income was recorded in the prior year period.

NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. The recognition of mark-to-market gain and dividend income compensated for the decline in operating income. Income before income tax for the second quarter increased by 8.4% YoY to RMB156.2 million ($23.0 million). Income tax expense for the second quarter was RMB22.9 million ($3.4 million). Net income attributable to the Company's shareholders for the reporting quarter increased by 9.2% YoY to RMB131.4 million ($19.4 million). Net margin for the reporting quarter improved to 46.0% from 38.4% in the prior year period.

EARNINGS PER SHARE. Basic and diluted earnings per ordinary share for the second quarter of fiscal 2021 was RMB1.08 ($0.16).

First Half of Fiscal 2021 Financial Results

For the first half of fiscal year 2021, total revenues decreased by 3.5% YoY to RMB566.5 million ($83.4 million). The decrease was mainly due to the decline in new subscribers. Revenues from processing fees and other services decreased by 11.4% YoY to RMB325.9 million ($48.0 million), whereas revenues from storage fees increased by 10.0% YoY to RMB240.6 million ($35.4 million). Gross profit decreased by 2.9% YoY to RMB478.4 million ($70.5 million). Operating income increased by 6.2% YoY to RMB272.7 million ($40.2 million). Non-GAAP operating income[2] increased by 5.5% YoY to RMB297.3 million ($43.8 million). Net income attributable to the Company's shareholders improved by 15.4% to RMB263.9 million ($38.9 million). Basic and diluted earnings per ordinary share was RMB2.17 ($0.32). Net cash provided by operating activities in the first half of fiscal 2021 was RMB274.6 million ($40.5 million).

Corporate Developments

On June 4, 2019, the Board of Directors of the Company (the "Board") received a non-binding proposal letter from Cordlife Group Limited ("Cordlife"), a company listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX"), pursuant to which Cordlife proposed to combine the businesses of Cordlife and the Company, by way of a statutory merger. According to the letter, Cordlife would issue approximately 2,497.9 million ordinary shares at an issue price of SGD0.5 per ordinary share in exchange for all of the outstanding ordinary shares of the Company at $7.50 per ordinary share. Upon completion of the proposed transaction, the Company's ordinary shares would be delisted from the New York Stock Exchange, and Cordlife ordinary shares would continue to trade on the SGX. On June 5, 2019, the Board formed a special committee of independent directors (the "Special Committee") who are not affiliated with Cordlife to evaluate such proposal.

On November 11, 2019, the Company appointed Mr. Jack Chow as an independent non-executive director ("INED") of the Board. Mr. Chow has extensive professional experience and a broad network in the finance and investment industry. He replaced Mr. Mark Chen as a member of the Audit Committee and Ms. Jennifer Weng as a member of the Special Committee. Mr. Chow also joined the Board's Compensation Committee and Nominating and Corporate Governance Committee.

On February 6, 2020, the Company appointed Mr. Jacky Cheng as an INED of the Board. Mr. Cheng has extensive professional experience and knowledge in legal and compliance and Chinese laws. He joined the Board's Compensation Committee as a member and the Company's Special Committee as a member. Currently, the Special Committee is composed of four members, including Mr. Mark Chen, Dr. Ken Lu, Mr. Jack Chow, and Mr. Jacky Cheng.

The Company cautions its shareholders and others considering trading its ordinary shares that no decisions have been made with respect to the Company's response to the proposed transaction with Cordlife. The proposed transaction is still subject to various conditions, including but not limited to, completion of due diligence, parties entering into a definitive agreement, and/or each of Cordlife and the Company obtaining its relevant regulatory and shareholder approvals. In addition, litigation has been filed in the Cayman Islands challenging the proposed transaction. There can be no assurance that any definitive offer will be made, that any agreement will be executed, or that this or any other transaction will be approved or consummated.

Conference Call

The Company will host a conference call at 8:00 a.m. ET on Wednesday, November 25, 2020, to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company's IR website at http://ir.globalcordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for seven days at the same URL above. Listeners can also access the call by dialing 1-646-722-4977 or 1-855-824-5644 for US callers, or +852-3027-6500 for Hong Kong callers, access code: 84298954#.

Use of Non-GAAP Financial Measures

GAAP results for the three months and six months ended September 30, 2020, include non-cash items related to depreciation and amortization expenses. To supplement the Company's unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure of U.S. GAAP; however, the Company's management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company's historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.

About Global Cord Blood Corporation

Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at: http://www.globalcordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: the effects of the current COVID-19 outbreak, including the inability of the Company's salesforce to return to work due to current lockdowns implemented in various cities in the PRC and the imposition by some hospitals in the PRC of restrictions on entrance to solely to hospital staff and patients; levels of consumer confidence in the healthcare services sector generally in the PRC as a result of the outbreak; the length of the COVID-19 outbreak and severity of such outbreak across the globe; the pace of recovery following the COVID-19 outbreak; continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of legislative developments in the U.S. affecting listed issuers whose independent registered public accounting firms are based in China and not subject to U.S. Public Company Accounting Oversight Board inspections, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions; the non-binding proposal letter from Cordlife and the potential transaction contemplated by such letter, and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the period ended September 30, 2020 were made at the noon buying rate of RMB6.7896 to $1.00 on September 30, 2020 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. Global Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

For more information, please contact:

Global Cord Blood Corporation Investor Relations Department Tel: (+852) 3605-8180 Email: ir@globalcordbloodcorp.com

ICR, Inc. William Zima Tel: (+86) 10-6583-7511 U.S. Tel: (646) 405-5185 Email: William.zima@icrinc.com

View original content: http://www.prnewswire.com/news-releases/global-cord-blood-corporation-reports-financial-results-for-the-second-quarter-and-first-half-of-fiscal-2021-301179591.html

SOURCE Global Cord Blood Corporation

See the rest here:

Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2021 - Galveston County Daily News

Read more
Global Stem Cell Banking Market to Get Expansion admist COVID 19, Scope With Advanced Technologies Top Key Players and Forecast 2020-2027 – The…

Databridgemarketresearch.com Present Global Stem Cell Banking Market Industry Trends and Forecast to 2027 new report to its research database. The report spread No of pages: 350 No of Figures: 60 No of Tables: 220 in it. This Global Stem Cell Banking Market report takes into consideration diverse segments of the market analysis that todays business ask for. The Global Stem Cell Banking Market report provides estimations of CAGR values, market drivers and market restraints about the industry which are helpful for the businesses in deciding upon numerous strategies. The base year for calculation in the report is taken as 2017 whereas the historic year is 2016 which will tell you how the Global Stem Cell Banking Market is going to perform in the forecast years by informing you what the market definition, classifications, applications, and engagements are. The report helps you to be there on the right track by making you focus on the data and realities of the industry.

The research studies of this Global Stem Cell Banking Market report helps to evaluate several important parameters that can be mentioned as investment in a rising market, success of a new product, and expansion of market share. Market estimations along with the statistical nuances included in this market report give an insightful view of the market. The market analysis serves present as well as future aspects of the market primarily depending upon factors on which the companies contribute in the market growth, crucial trends and segmentation analysis. This Global Stem Cell Banking Market research report also gives widespread study about different market segments and regions.

Global stem cell banking market is set to witness a substantial CAGR of 11.03% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. The increased market growth can be identified by the increasing procedures of hematopoietic stem cell transplantation (HSCT), emerging technologies for stem cell processing, storage and preservation. Increasing birth rates, awareness of stem cell therapies and higher treatment done viva stem cell technology.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-banking-market&pm

Competitive Analysis:

Global stem cell banking market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of inflammatory disease drug delivery market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors:

Few of the major competitors currently working in global inflammatory disease drug delivery market are: NSPERITE N.V, Caladrius, ViaCord, CBR Systems, Inc, SMART CELLS PLUS, LifeCell International, Global Cord Blood Corporation, Cryo-Cell International, Inc., StemCyte India Therapeutics Pvt. Ltd, Cordvida, ViaCord, Cryoviva India, Vita34 AG, CryoHoldco, PromoCell GmbH, Celgene Corporation, BIOTIME, Inc., BrainStorm Cell Therapeutics and others

Market Definition:Global Stem Cell Banking Market

Stem cells are cells which have self-renewing abilities and segregation into numerous cell lineages. Stem cells are found in all human beings from an early stage to the end stage. The stem cell banking process includes the storage of stem cells from different sources and they are being used for research and clinical purposes. The goal of stem cell banking is that if any persons tissue is badly damaged the stem cell therapy is the cure for that. Skin transplants, brain cell transplantations are some of the treatments which are cured by stem cell technique.

Cord Stem Cell Banking MarketDevelopment and Acquisitions in 2019

In September 2019, a notable acquisition was witnessed between CBR and Natera. This merger will develop the new chances of growth in the cord stem blood banking by empowering the Nateras Evercord branch for storing and preserving cord blood. The advancement will focus upon research and development of the therapeutic outcomes, biogenetics experiment, and their commercialization among the global pharma and health sector.

Cord Stem Cell Banking MarketScope

Cord Stem Cell Banking Marketis segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of the cord stem cell banking marketis further analyzed based on maximum granularity into further segmentation. On the basis of storage type, the market is segmented into private banking, public banking. On the basis of product type, the market is bifurcated into cord blood, cord blood & cord tissue. On the basis of services type, the market is segmented into collection & transportation, processing, analysis, storage. On the basis of source, market is bifurcated into umbilical cord blood, bone marrow, peripheral blood stem, menstrual blood. On the basis of indication, the market is fragmented into cerebral palsy, thalassemia, leukemia, diabetes, autism.

Cord stem cell trading is nothing but the banking of the vinculum plasma cell enclosed in the placenta and umbilical muscle of an infant. This ligament plasma comprises the stem blocks which can be employed in the forthcoming time to tackle illnesses such as autoimmune diseases, leukemia, inherited metabolic disorders, and thalassemia and many others.

Market Drivers

Increasing rate of diseases such as cancers, skin diseases and othersPublic awareness associated to the therapeutic prospective of stem cellsGrowing number of hematopoietic stem cell transplantations (HSCTs)Increasing birth rate worldwide

Market Restraint

High operating cost for the therapy is one reason which hinders the marketIntense competition among the stem cell companiesSometimes the changes are made from government such as legal regulations

Key Pointers Covered in the Cord Stem CellBanking MarketIndustry Trends and Forecast to 2026

Market SizeMarket New Sales VolumesMarket Replacement Sales VolumesMarket Installed BaseMarket By BrandsMarket Procedure VolumesMarket Product Price AnalysisMarket Healthcare OutcomesMarket Cost of Care AnalysisMarket Regulatory Framework and ChangesMarket Prices and Reimbursement AnalysisMarket Shares in Different RegionsRecent Developments for Market CompetitorsMarket Upcoming ApplicationsMarket Innovators Study

Key Developments in the Market:

In August, 2019, Bayer bought BlueRock for USD 600 million to become the leader in stem cell therapies. Bayer is paying USD 600 million for getting full control of cell therapy developer BlueRock Therapeutics, promising new medical area to revive its drug development pipeline and evolving engineered cell therapies in the fields of immunology, cardiology and neurology, using a registered induced pluripotent stem cell (iPSC) platform.In August 2018, LifeCell acquired Fetomed Laboratories, a provider of clinical diagnostics services. The acquisition is for enhancement in mother & baby diagnostic services that strongly complements stem cell banking business. This acquisition was funded by the internal accruals which is aimed to be the Indias largest mother & baby preventive healthcare organization.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-banking-market&pm

Research objectives

To perceive the most influencing pivoting and hindering forces in Cord Stem Cell Banking Market and its footprint in the international market.Learn about the market policies that are being endorsed by ruling respective organizations.To gain a perceptive survey of the market and have an extensive interpretation of the Cord Stem Cell Banking Market and its materialistic landscape.To understand the structure of Cord Stem Cell Banking Market by identifying its various sub segments.Focuses on the key global Cord Stem Cell Banking Market players, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Cord Stem Cell Banking Market submarkets, with respect to key regions (along with their respective key countries).To strategically profile the key players and comprehensively analyze their growth strategiesTo analyze the Cord Stem Cell Banking Market with respect to individual growth trends, future prospects, and their contribution to the total market.

Customization of the Report:

All segmentation provided above in this report is represented at country levelAll products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

View post:

Global Stem Cell Banking Market to Get Expansion admist COVID 19, Scope With Advanced Technologies Top Key Players and Forecast 2020-2027 - The...

Read more
Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act – Stockhouse

Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.

Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine market

The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The North America region is projected to grow at the highest CAGR during the forecast period in 2019. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

Market Dynamics

Drivers

Restraints

Opportunities

Impact of the COVID-19 Pandemic on the Regenerative Medicine Market

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/6v7acf

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post here:

Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act - Stockhouse

Read more
Application and Product Portfolio Analysis During the forecasted period of Stem Cell Banking Market – The Think Curiouser

The Stem Cell Banking Market research report recently presentedby Prophecy Market Insights which provides reliable and sincere insights related to the various segments and sub-segments of the market. The market study throws light on the various factors that are projected to impact the overall dynamics of the Stem Cell Banking market over the forecast period (2019-2029).

Influences of the market report:

An executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Stem Cell Banking market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/281

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

Australia, New Zealand, Rest of Asia-Pacific

Stakeholders Benefit:

Segmentation Overview:

The Stem Cell Banking research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Stem Cell Banking market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/281

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Highlights of the Report

Complete access to COVID-19 Impact on the Stem Cell Banking market dynamics, key regions, market size, growth rate and forecast to 2029

The report on the Stem Cell Banking market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Some important Questions Answered in Stem Cell Banking Market Report are:

Stem Cell BankingMarket by Top Manufacturers:

Cryo-cell International, Inc., Stem Cyte, Inc., ViaCord, Inc., Cord Blood Registry , Inc., SmartCells, Inc., LifeCell International Pvt.Ltd, Cryoviva Biotech Pvt. Ltd., Cryo StemcelPrivate Limited, Reliance Life Sciences Private Limited, and Trascell Biolife Pvt. Ltd.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/281

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

The rest is here:

Application and Product Portfolio Analysis During the forecasted period of Stem Cell Banking Market - The Think Curiouser

Read more
Why Bank Cord Blood & Tissue? Is Banking Worth It? | Cryo-Cell

Add Cord Blood Banking to the Checklist

The big questions parents have when considering cord blood and cord tissue banking are why should they bank and is it worth it. While some parents may choose banking because of their family history and others may choose it for added peace of mind, the underlying reason is to help ensure their childs and familys future health and well-being. Why to bank cord blood and why to bank cord tissue are ultimately medical decisions based on the relatively recent discovery of where to find and isolate stem cells and the growing use of these stem cells in the treatment of diseases. Cord blood and cord tissue contain an abundance of stem cells that can easily be collected and banked (cryopreserved) in the event that they are needed later in life.

Cord blood is currently used in the treatment of more than 80 diseases. For instance, when someone contracts a disease that must be treated with chemotherapy or radiation, there is a high probability of a negative impact on the immune system. A particular type of stem cell found in cord blood is used to bolster and re-populate the cells in the blood and immune system. Leukemia is a disease where chemotherapy is often used to rid the body of the cancerous blood cells, but it takes its toll on the bodys normal blood-forming cells, too. Stem cell transplants infuse the body with the blood-forming cells it needs to recover, effectively replacing the old cells with new, healthy cells.

Stem cells used in transplants were first obtained through bone marrow. In 1978, science discovered stem cells in the umbilical cord blood, and in 1988, cord blood stem cells were used in their first transplant. Cord blood banking has since been determined to be the preferred source of stem cells for a transplant: Cord blood can be used in partial matches and shows a reduced risk of post-transplantation complications. Cord blood is also easy to collect at the time of delivery and is immediately available when needed. (Follow the link at the bottom of the page for a more in-depth look at cord blood's benefits.)

It was soon after that first transplant that some of the first private cord blood banks were established to provide parents the opportunity to store their baby's cord blood. In fact, Cryo-Cell is the worlds first private cord blood bank. Later on, Cryo-Cell's banking process was licensed to companies around the globe. Those companies have grown to become some of the largest cord blood banking companies in Europe, India, Mexico and other countries, providing families in those areas access to therapies using their own child's stem cells.

Beyond the current treatments, the possible uses of cord blood have not been completely defined, and clinical trials are underway for its use as a regenerative therapy in strokes, heart disease, diabetes and more.

We are living in an exciting era of regenerative medicine. Stem cells are currently being studied in numerous clinical trials for regenerative purposes. Many of these studies involve cells from the umbilical cord tissue. These stem cells are being used to rebuild cardiac tissue, repair neural or spinal cord injuries, heal connective tissues damaged in sports injuries, reverse the effects of autism, Alzheimers and Parkinson's and build new organs. While research is still in its early stages, the possibilities are extremely promising.

In 1991, scientists figured out that the umbilical cord itself is a rich source of a different type of stem cell. These cells have many special functions that fill a need in regenerative medicine. The bodys ability to regenerate tissues through its own stem cells is limited and slows further with age. For instance, a heart attack will leave behind scar tissue that lacks muscle or blood vessels. Any part of the heart, which is basically a big muscle, that cant contract and limits the ability to pump blood could lead to further complications. Scientists are hopeful that cord tissue stem cells could one day prove effective in this type of treatment.

The stem cells from cord tissue banking do share some of these benefits with cord blood but also have many benefits of their own including the ability to inhibit inflammation following tissue damage, to secrete growth factors that aid in tissue repair and to become one of many cell types found in your nervous system, sensory organs, circulatory tissues, skin, bone, cartilage and more. It is in the repair of tissues in these areas where cord tissue stem cells look promising.

Saving your childs stem cells is an investment toward your familys future health. The value of one's health and its effects on the quality of life are difficult to quantify in financial terms. For most, it is probably priceless. Like saving for retirement when you're young or purchasing health insurance when you're perfectly healthy, the benefits of banking cord blood are not always immediate and can seem out of reach or too distant to worry about. It more personally and intimately affects people who have conditions that run in their families, have seen first-hand the effects leukemia or sickle cell can have on an entire family or live with a loved one suffering from Alzheimer's or the effects of a stroke and aspire for the day when there will be ways to better treat such conditions. This is when it is important to remember that the diseases that cord blood treats can have an impact on anyone, from all walks of life, and with its potential in regenerative medicine still being discovered, it will hit closer to home for many more people as time passes.

If, however, one must make economic justifications, the cost of storing cord blood and tissue is much lower than other means of trying to combat the diseases it treats. These costs go beyond the $40,000 it currently takes to retrieve a match from a public cord bank and includes the precious weeks and months it takes to try to find a public match and the anxiety during that time wondering if there even is a match. In the end, the potential return on this investment in terms of financial costs and peace of mind is high but still subordinate to the fact that it can save the life of a loved one.

Still want to learn more? We are here to answer any question you may have and can send you any information about cord blood and cord tissue banking that you need.

View post:

Why Bank Cord Blood & Tissue? Is Banking Worth It? | Cryo-Cell

Read more